<DOC>
	<DOCNO>NCT00741884</DOCNO>
	<brief_summary>The purpose study evaluate safety , efficacy , tolerability twice daily ( BID ) administration three dose strength ( 1.2 mg , 1.8 mg , 2.4 mg ) varenicline control release ( CR ) tablets adult smoker .</brief_summary>
	<brief_title>A Study Evaluate Safety Efficacy Three Doses Controlled Release Formulation Varenicline Smoking Cessation</brief_title>
	<detailed_description />
	<mesh_term>Varenicline</mesh_term>
	<criteria>Male female cigarette smoker age 18 75 year , inclusive , motivate stop smoking . Females nonchildbearing potential ( surgically sterilize least 2 year postmenopausal ) nursing may include . Subjects must smoke average least 10 cigarette per day past year month prior screen visit , period abstinence great 3 month past year . Subjects clinically significant cardiovascular disease past 6 month . Subjects hospitalize within past 12 month due suicidal ideation suicidal behavior subject consider serious suicidal ideation suicidal behavior within past 12 month . Subjects active suicidal ideation behavior identify Screen Baseline . Subjects currently within past 12 month require treatment depression . Subjects current prior history panic disorder , anxiety disorder , hostility aggression disorder , perceptual/thinking disturbance , psychosis , bipolar disorder .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>April 2015</verification_date>
</DOC>